MRSN - Mersana Therapeutics, Inc.
IEX Last Trade
1.42
-0.030 -2.113%
Share volume: 11,576
Last Updated: Fri 27 Dec 2024 05:30:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$1.45
-0.03
-2.07%
Fundamental analysis
25%
Profitability
25%
Dept financing
19%
Liquidity
65%
Performance
15%
Performance
5 Days
5.88%
1 Month
-25.35%
3 Months
-12.43%
6 Months
-19.80%
1 Year
-25.69%
2 Year
-71.63%
Key data
Stock price
$1.42
DAY RANGE
$1.40 - $1.50
52 WEEK RANGE
$1.36 - $6.28
52 WEEK CHANGE
-$30.77
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Anna Protopapas
Region: US
Website: mersana.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: mersana.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.
Recent news